OSEM™ combines a proprietary AI-refined risk score, clinically tested products, and nurse-led monitoring to reduce treatment related side effects, improve clinical outcomes and reduce cost of care. It is now available to all health plans, oncology practices and pharmaceutical companies.
DUNEDIN, Fla., Nov. 10, 2026 /PRNewswire-PRWeb/ -- (un)cancer today announced that OSEM™ (Oncology Side-Effect Management), the first platform built exclusively to manage cancer treatment side effects, is now available to all health plans, oncology practices, health systems and pharmaceutical companies. OSEM™ is designed to catch side effects earlier, at home, and connect patients to their oncology teams.
Most side effects start at home, between visits, where care teams cannot see them. In one study of commercially insured patients, about half of emergency visits in the first year of cancer treatment were potentially preventable.(1)
"Our programs already help patients manage side effects at home, between visits," said Abida Taher, MD, PhD, founder and CEO of (un)cancer. "OSEM™ brings that work into one program, and now we're opening it up beyond our first partners."
How OSEM™ works
- Risk scoring: an AI-enabled score flags who needs more help before the first dose.
- At-home care: risk-matched products and education arrive before treatment starts.
- Monitoring and escalation: nurse check-ins address any side effect a patient reports and escalate to the patient's oncology team.
- Protocols: starting with oral side effects, expanding to GI, skin, infection and neuropathy.
"Every flag goes to a person," said Nars Krishnamachari, MS, chief technology officer. "AI does the sorting; our care team and the patient's own oncologists make the clinical decisions."
OSEM™ builds on published research showing that structured symptom monitoring during chemotherapy can reduce emergency visits(2). Its oral side-effect program is being evaluated in an IRB-approved randomized pilot study in adults receiving radiation for head and neck cancer (NCT07885033).
"We started with mouth sores because they show how fast a manageable side effect becomes disruptive," said Robyn Lesser, DMD, co-founder of (un)cancer.
"Managing side effects has remained largely uncharted territory for health plans, and one of the clearest places to improve outcomes and control avoidable cost at the same time," said Somesh Nigam, PhD, health economics advisor to (un)cancer.
To learn more or request a briefing, visit OSEM™.
(1) Panattoni L, et al. J Oncol Pract. 2018;14(3):e176–e185. (2) Basch E, et al. J Clin Oncol. 2016;34(6):557–565.
Media Contact
Robyn Lesser, Co-Founder, uncancer, 1 844-806-0124, [email protected], www.uncancer.com
SOURCE uncancer
Share this article